Management Team

Founding partner of New Value Capital, one of the earliest management consulting experts in China engaged in enterprise strategic management, business model innovation, corporate governance, human resources, capital operation, production and supply chain management, etc. I have served as a course professor and visiting professor at several well-known business schools in China, specializing in areas such as strategy and business model innovation, macroeconomics and capital markets, and venture capital. I have served as Senior Vice President and Chinese person in charge of three large foreign enterprises, mentoring and training thousands of Chinese and foreign enterprises, and familiar with various aspects of enterprise operation and management. Successful investment cases include hard technology and biopharmaceutical projects such as Xingyuan Materials, Western Superconductor, Hequan Pharmaceutical, Xinda Biology, Junshi Biology, Pumen Technology, Kangxinuo, Lehe Food, Huanchuang Technology, Laihua Video, Frontier Biology, Alpha Molecular, Zolin Biology, Fengjia Microelectronics, Shengnuoji Biology, Qiyu Biology, and Fushi Technology. Member of the Board of Directors of the China Association for Venture Capital and the Central Committee of the People's Republic of China and the China Venture Capital Research Institute In recent years, as a guest speaker, I have given speeches on macroeconomics and capital markets, venture capital and equity investment at multiple universities, business schools, and professional forums.

Doctorate in Economic Law, School of Law, Renmin University of China Chief Management Partner, Director of the Business Development Committee, and Head of the Investment and Mergers and Acquisitions Division of Beijing Longan (Shenzhen) Law Firm. Member of the Financial and Legal Professional Committee of the Shenzhen Bar Association, and member of the International and Hong Kong Macao Taiwan Cooperation Committee of the Shenzhen Bar Association. Special Legal Advisor for Legislation of Shenzhen Qianhai Shenzhen Hong Kong Modern Service Industry Cooperation Zone Management Bureau, Certified as an Independent Director of a Listed Company by the Shanghai Stock Exchange. Focusing on corporate mergers and acquisitions, listing and financing on the New Third Board, financing for unlisted companies, disposal of non-performing assets in banks, and foreign-related commercial services. I have provided legal services for mergers and acquisitions of multiple Chinese and Hong Kong listed companies, and provided legal services for listing and financing on the New Third Board for more than 20 enterprises. Published a legal monograph titled "Research on Legal Regulations for the Disposal of Non performing Assets in Banks", which was selected as an internal training textbook for the China Banking Association in 2014.

Master of Economics and Management from Manchester Business School in the UK Bachelor of Business Accounting, McGuire University, Australia Vice Chairman of the Hong Kong Toy Association, winner of the 2013 Hong Kong Young Industrialist Award, and member of the Toy Advisory Committee of the Hong Kong Trade Development Council. Having nearly 10 years of investment and capital operation experience, skilled in collaborating with overseas banks and investment banks (including Morgan Stanley, Blackstone, HSBC, Standard Chartered, etc.). The family manages an enterprise with an annual output value of 1 billion RMB, total assets exceeding 5 billion RMB, and nearly 20000 employees. In recent years, I have been paying attention to investments in mainland China and have successfully invested in a Hong Kong group, Playhouse, Migsbus, Shangfang Health, Jiangxi Qinye Garden, Chagao Motor, and Qinye Industry.

Master's degree in Microbiology and Virology at Wuhan University He was once engaged in virology research in the State Key Laboratory of Virology, Wuhan University. I have been engaged in research on IPS stem cell therapy, which won the Nobel Prize, and later served as the Project&Technical Director at Topper Biology. I have rich experience in preclinical research of drugs, especially in experimental design, coordination and arrangement of experiments, and data analysis of drugs. Since joining New Value Capital, I have been responsible for completing leading investments in projects such as Biotech, Zolin Biology, and Senruis (two consecutive rounds).

Master's degree in Biological Science and Technology at Michigan Institute of Technology in the United States I have nearly 3 years of experience in biopharmaceutical engineering. Previously worked as a research assistant at SYNTRON BIORESEARCH in California, USA, responsible for analyzing macromolecular data such as proteomic data, antibody immunoassay, and antibody hybridization data. Drive product improvement, etc. Develop data models and maintain routes and materials for drug production processes, as well as other market development related tasks. Familiar with the entire process of macromolecular drug research and development, with rich work experience. Mainly responsible for industry research and investment in new drug research and development, drug synthesis, healthcare, and other related fields.

Master's degree in Pharmacy, Jinan University Formerly a Brooke Protein Mass Spectrometry engineer, participated in the construction of the National Protein Science Center - Insight Project, responsible for the construction of the first microliter protein mass spectrometry platform in China and the research and development of single-cell proteomics. Proficient in discovering disease targets, constructing in vitro and in vivo models, and conducting pharmacological research. Proficient in utilizing multi omics to identify potential targets, focusing on the hardware core components of medical equipment. Currently, I am mainly responsible for research and investment in related fields such as biotechnology, pharmaceutical experimental equipment, and innovative drugs.

PhD in Chemistry at Nankai University Postdoctoral fellow at Southern University of Science and Technology During the doctoral stage, I studied and studied organic chemistry under Academician Cheng Jinpei, and during the postdoctoral period, I was engaged in the study of total synthesis of bioactive natural products. He has conducted academic exchanges and research work in Tianjin International Institute of Biomedicine and Institute of Chemistry, Chinese Academy of Sciences. Dr. Xi is proficient in fields such as organic synthetic chemistry, pharmaceutical chemistry, and the synthesis of bioactive compounds. I have mainly been responsible for or participated in sub projects of the National 973 Program, major projects of the National Natural Science Foundation of China, and other major projects. I have published high-level academic research papers in international authoritative journals such as Journal Of OrganicChemistry, Organic Letters, and Advanced Synthesis&Analysis. Dr. Xi is mainly responsible for the company's new drug research and development, drug synthesis, medical and health related industries.

Bachelor's degree from West China Medical University Master's degree in Economics from Renmin University of China Registered with securities investment consulting, securities issuance and underwriting, and securities brokerage qualification certificates in 2001. I have nearly 30 years of experience in investing in primary and secondary capital markets both domestically and internationally, and have achieved outstanding performance during my tenure as a manager of non sunshine private equity funds in Hong Kong. Accustomed to extrapolating investment opportunities and risks from mature secondary markets to primary markets, often able to sniff investment traps from limited information. Partner of the company, member of the decision-making committee, and head of the biomedical team. Since joining in early 2016, I have been involved in investing in projects such as Pumen Technology, Frontier Biology, and Shengnuoji; I personally led the investment in projects such as Hequan Pharmaceutical, 688122. SH Western Superconductor, Qiyu Biology, and Alpha Molecule (Seed Wheel), and personally led the post investment precision exit of 688389. SH Pumen Technology (from June 21, 2021 to June 28, 2021, with a starting price of 30.00, a maximum price of 31.61, and a middle price of 30.53); Lead the biomedical team to complete investments in projects such as Zolin Biology, Biotech, and Senruis.

Finance major at Renmin University of China Master's degree from the University of Hong Kong I have nearly 8 years of work experience in the field of equity investment, with complete experience in leading fundraising, investment, management, and retirement. I have promoted the implementation of multiple equity investment projects, am familiar with investment projects in the high-tech and consumer fields, have worked with government guided funds, and have experience as a partner in a venture capital company. Having a professional perspective and investment partner perspective, with keen insight into identifying investment project opportunities, and in-depth experience in risk assessment, business negotiation, and key clause control of investment projects. Mainly responsible for industry investment in the company's semiconductor, advanced manufacturing, and artificial intelligence related fields.

Master's degree from Changchun Institute of Space Optoelectronics Technology, Chinese Academy of Sciences Master's degree in China Business Administration, Hong Kong Polytechnic University During my time at the research institute, I participated in the GEO Earth Link Laser Communication and LEO Intersatellite Link Laser Communication projects and research projects. Having more than four years of experience in the equity investment industry, possessing rich project resources, professional investment feasibility analysis and project decision-making abilities, particularly adept at capturing and grasping investment opportunities in fields such as semiconductor high-end equipment, advanced manufacturing automation, and new energy storage equipment, and engaging in related industry research and investment work.

PhD in Nanoscience from Delft University of Technology in the Netherlands Dual degrees in Materials Physics and Finance from Wuhan University I have worked at Tianfeng Securities, Shanghai Xiangda Fund, Hubei Hongtai Group, and Changjiang Industry Group, with over ten years of experience in industry and venture capital fund management. Mainly focusing on information technology (industrial control and industrial software, enterprise services, semiconductor equipment and materials, chips, electronic manufacturing, communication technology), industrial interconnection and advanced manufacturing, high-end equipment, new materials, new energy and new energy vehicle power devices and core components.

Bachelor of Computer Science and Technology Experimental Class, Tsinghua University PhD in Computer Science and Technology at Tsinghua University Joint training of postdoctoral fellows at Tsinghua University and the University of Hong Kong Dr. Gu's main research areas are network science and artificial intelligence, specializing in algorithm design and analysis. Dr. Gu has rich academic research achievements and project research experience in the field of computer science. He has published dozens of papers at computer science conferences and participated in multiple cutting-edge technology research worldwide. Dr. Gu is mainly responsible for industry research and investment in the company's artificial intelligence, data science, deep learning algorithms, and other related fields.

Master of Law from Tsinghua University Lawyer Yu mainly focuses on legal business fields such as corporate mergers and acquisitions, listing and financing on the New Third Board, private equity investment funds, trusts, corporate bonds, equity incentives, and corporate governance structure standardization. He has a solid professional foundation and rich practical experience. Lawyer Yu is mainly responsible for the company's legal affairs, risk control, and post investment management related projects. Formerly served as the keynote lawyer for the "Private Equity Hui" program on Shenzhen TV's financial channel.

Master of Laws from the University of Wisconsin, USA Master's and Bachelor's degree in Law from East China University of Political Science and Law Possess legal professional qualification certificates and securities industry qualification certificates. Previously worked at Guohao Law Firm (Shenzhen) and Beijing Jingshi Law Firm (Shenzhen), familiar with relevant laws and regulations of financial institutions, proficient in companies, securities, investment and other fields, and familiar with various risks in the operation of financial products. Currently, I am mainly responsible for daily legal affairs, risk control, and post investment management of the company.